EPAS1 and nonpapillary renal cell carcinoma: Nevertheless, there is currently a Phase III clinical trial (NCT04195750) aiming to compare the efficacy and safety of HIF-2α inhibitor MK-6482 (also known as WELIREG) with the mTOR inhibitor everolimus in previously treated advanced ccRCC patients.